Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.72 USD | 0.00% | -6.53% | -60.44% |
May. 20 | SAB Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 06 | SAB Biotherapeutics, Inc. Appoints Jay Skyler, Md, to the Board of Directors | CI |
Financials (USD)
Sales 2024 * | 922K | Sales 2025 * | - | Capitalization | 25.09M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -47M | EV / Sales 2024 * | 27.2 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.68
x | P/E ratio 2025 * |
-0.62
x | Employees | 57 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.4% |
1 week | -6.53% | ||
Current month | -36.60% | ||
1 month | -35.08% | ||
3 months | -35.55% | ||
6 months | -70.43% | ||
Current year | -60.44% |
Managers | Title | Age | Since |
---|---|---|---|
Eddie Sullivan
FOU | Founder | 58 | 21-10-21 |
Samuel Reich
CEO | Chief Executive Officer | 49 | 21-10-21 |
Michael King
DFI | Director of Finance/CFO | 63 | 23-10-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 68 | 21-10-21 | |
Jeffrey Spragens
BRD | Director/Board Member | 82 | 21-10-21 |
Erick Lucera
BRD | Director/Board Member | 57 | 23-04-02 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 2.72 | 0.00% | 3 483 |
24-05-24 | 2.72 | +5.02% | 14,480 |
24-05-23 | 2.59 | -8.80% | 47,992 |
24-05-22 | 2.84 | -2.41% | 57,292 |
24-05-21 | 2.91 | -15.65% | 355,156 |
Delayed Quote Nasdaq, May 28, 2024 at 03:50 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.44% | 25.09M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- SABS Stock